Event Group
Event Groups are part of the Adverse Events Module within the Results Section. They provide a way to organize and summarize adverse event data by grouping related events together.
Each Event Group typically represents a category or class of adverse events and includes statistical information such as the number of participants affected and at risk for different event types: deaths, serious events, and other events.
Event Group path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Group
Event Group
Ignite Creation Date:
2025-12-25 @ 2:29 AM
Ignite Modification Date:
2025-12-26 @ 1:04 AM
NCT ID:
NCT02975934
Group ID:
EG002
Title:
Rucaparib (Cross-over Phase)
Description:
Oral rucaparib (monotherapy). Rucaparib: Rucaparib will be administered daily. Participants from the Abiraterone Acetate/Enzalutamide/Docetaxel arm who completed the Treatment Phase and radiographically progressed by independent radiology review (IRR) may receive rucaparib treatment during the Cross-Over Phase.
After analysis of the primary endpoint, investigator-assessed radiographic disease progression will be used for cross-over eligibility evaluation.
Deaths Number Affected:
1
Deaths Number At Risk:
None
Serious Number Affected:
18
Serious Number At Risk:
70
Other Number Affected:
67
Other Number At Risk:
70
Study:
NCT02975934
Results Section:
NCT02975934
Adverse Events Module:
NCT02975934